NCT04992299

Brief Summary

Rates of type 2 diabetes (T2D) in adolescents have escalated. Adolescent-onset is associated with greater health comorbidities and shorter life expectancy than adult-onset T2D. T2D is preventable by decreasing insulin resistance, a physiological precursor to T2D. T2D prevention standard-of-care is lifestyle intervention to decrease insulin resistance through weight loss; yet, this approach is insufficiently effective in adolescents. Adolescents at risk for T2D frequently experience depression, which predicts worsening insulin resistance and T2D onset, even after accounting for obesity. Mindfulness-based intervention (MBI) may offer a targeted, integrative health approach to decrease depression, and thereby, ameliorate insulin resistance in adolescents at risk for T2D. In a single-site, pilot randomized controlled trial (RCT), we established initial feasibility/acceptability of a 6-week group MBI program, Learning to BREATHE, in adolescents at risk for T2D. We demonstrated feasible single-site recruitment, randomization, retention, protocol adherence, and MBI acceptability/credibility in the target population. Our preliminary data also suggest MBI may lead to greater reductions in stress-related behavior, vs. CBT and a didactic/health education (HealthEd) control group. The current study is multisite, pilot RCT to test multisite fidelity, feasibility, and acceptability in preparation for a future multisite efficacy trial that will have strong external validity, timely recruitment, and long-term follow-up. Adolescents (N=120) at risk for T2D will be randomized to MBI vs. CBT vs. HealthEd and followed for 1-year. Specific aims are to: (1) test multisite fidelity of training and implementation of 6-week group MBI, CBT, and HealthEd, to teens at risk for T2D; (2) evaluate multisite feasibility/acceptability of recruitment, retention, and adherence for an RCT of 6-week group MBI, CBT, HealthEd with 6-week and 1-year follow-up; and (3) modify intervention training/implementation and protocol procedures in preparation for a future, fully-powered multisite efficacy RCT.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for not_applicable type-2-diabetes

Timeline
Completed

Started May 2022

Typical duration for not_applicable type-2-diabetes

Geographic Reach
1 country

4 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 21, 2021

Completed
15 days until next milestone

First Posted

Study publicly available on registry

August 5, 2021

Completed
9 months until next milestone

Study Start

First participant enrolled

May 5, 2022

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 21, 2024

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 26, 2025

Completed
10 months until next milestone

Results Posted

Study results publicly available

April 2, 2026

Completed
Last Updated

April 2, 2026

Status Verified

March 1, 2026

Enrollment Period

2.6 years

First QC Date

July 21, 2021

Results QC Date

January 14, 2026

Last Update Submit

March 13, 2026

Conditions

Keywords

Adolescent DevelopmentObesityType 2 Diabetes

Outcome Measures

Primary Outcomes (2)

  • Intervention Fidelity

    Facilitators score ≥8 on adherence and competence ratings of MBI, CBT, and HealthEd adolescent group sessions (1=poor to 10=exceptional)

    12-months

  • Recruitment Feasibility: Percentage of Eligible Adolescents Who Enroll

    ≥80% eligible adolescents will enroll

    12-months

Secondary Outcomes (8)

  • Training Fidelity: Facilitator Knowledge After Training

    6-months

  • Training Fidelity: Facilitator Adherence and Competence During Mock Sessions

    6-months

  • Recruitment Feasibility

    24-months

  • Intervention Feasibility: Attendance

    6-weeks

  • Intervention Acceptability: Likeability/Credibility Ratings

    6-weeks

  • +3 more secondary outcomes

Study Arms (3)

Mindfulness-Based Intervention

EXPERIMENTAL

6-week group intervention, Learning to BREATHE, an adolescent mindfulness-based intervention derived from mindfulness-based stress reduction

Behavioral: Mindfulness-Based Intervention

Cognitive-Behavioral Therapy

ACTIVE COMPARATOR

6-week group intervention, the Blues Program, a cognitive-behavioral intervention for adolescents with elevated symptoms of depression

Behavioral: Cognitive-Behavioral Therapy

Health Education

OTHER

6-week group program providing didactic information on adolescent health topics

Behavioral: Health Education

Interventions

6-week mindfulness-based intervention of 6 weekly 1 hour group sessions

Mindfulness-Based Intervention

6-week cognitive-behavioral therapy intervention of 6 weekly 1 hour group sessions

Cognitive-Behavioral Therapy

6-week health education didactic program of 6 weekly 1 hour group sessions

Health Education

Eligibility Criteria

Age12 Years - 17 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Adolescent: Age 12-17 years
  • At-risk for T2D:
  • Overweight/obesity: BMI ≥85 percentile for age and sex Family history of T2D: ≥1 relative with T2D, prediabetes, or gestational diabetes in first- or second- degree relative, referring to a biological parent, sibling, aunt, uncle, or grandparent
  • Elevated depression symptoms: Center for Epidemiological Studies - Depression Scale (CES-D) total score \>20
  • Good general health: Medical history/physical examination
  • Parent/guardian: Parent/guardian of qualifying participant

You may not qualify if:

  • Major medical problem: including T2D, assessed at baseline/screening as fasting glucose ≥126 mg/dL or 2-hour glucose ≥200 mg/dL, or any other significant medical condition reported during the medical history/physical examination
  • Major psychiatric problem: Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 psychiatric diagnosis, including anorexia nervosa, bipolar disorder, bulimia nervosa, conduct disorder, major depressive disorder (MDD), obsessive compulsive disorder, panic disorder, posttraumatic stress disorder, psychosis, and substance/tobacco/alcohol use disorder
  • Regular medication use affecting mood, insulin, and/or weight: anti-anxiety medications, anti-depressants, anti-psychotics, insulin sensitizers, mood stabilizers, stimulants, and weight loss drugs
  • Active suicidal ideation or behavior
  • Regular psychotherapy or structured weight loss treatment
  • Pregnancy: as reported by adolescent participants (females)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

University of Colorado Denver/Children's Hospital Colorado

Aurora, Colorado, 80045, United States

Location

Colorado State University

Fort Collins, Colorado, 80523, United States

Location

Children's National Health System

Washington D.C., District of Columbia, 20010, United States

Location

Uniformed Services University

Bethesda, Maryland, 20814, United States

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2DepressionInsulin ResistanceObesity

Interventions

Cognitive Behavioral Therapy

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesBehavioral SymptomsBehaviorHyperinsulinismOverweightOvernutritionNutrition DisordersBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Behavior TherapyPsychotherapyBehavioral Disciplines and Activities

Limitations and Caveats

By design, this multisite pilot and feasibility randomized controlled trial was centered on the assessment of training and implementation fidelity and feasibility and acceptability of the study protocol and interventions. Intervention effects cannot be determined until a powered trial is undertaken.

Results Point of Contact

Title
Lauren Shomaker
Organization
Colorado State University

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 21, 2021

First Posted

August 5, 2021

Study Start

May 5, 2022

Primary Completion

December 21, 2024

Study Completion

May 26, 2025

Last Updated

April 2, 2026

Results First Posted

April 2, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

Data will be made available upon reasonable request.

Locations